Karyopharm Therapeutics (NASDAQ:KPTI) Stock Crosses Below 200 Day Moving Average - Time to Sell?

Karyopharm Therapeutics Inc. (NASDAQ:KPTI - Get Free Report)'s share price passed below its two hundred day moving average during trading on Monday . The stock has a two hundred day moving average of $0.76 and traded as low as $0.59. Karyopharm Therapeutics shares last traded at $0.62, with a volume of 791,301 shares.

Wall Street Analysts Forecast Growth

KPTI has been the topic of a number of research analyst reports. HC Wainwright reaffirmed a "buy" rating and set a $7.00 price target on shares of Karyopharm Therapeutics in a research report on Thursday. Royal Bank of Canada reaffirmed an "outperform" rating and set a $3.00 price target on shares of Karyopharm Therapeutics in a research report on Thursday. Piper Sandler upped their price target on shares of Karyopharm Therapeutics from $4.00 to $5.00 and gave the company an "overweight" rating in a research report on Wednesday, November 6th. Finally, StockNews.com cut shares of Karyopharm Therapeutics from a "buy" rating to a "hold" rating in a research report on Friday, November 22nd. One analyst has rated the stock with a hold rating and four have issued a buy rating to the company's stock. According to MarketBeat, Karyopharm Therapeutics presently has a consensus rating of "Moderate Buy" and an average target price of $5.00.

Karyopharm Therapeutics Price Performance

The firm's fifty day moving average price is $0.66 and its two-hundred day moving average price is $0.76. The stock has a market cap of $75.51 million, a price-to-earnings ratio of -0.59 and a beta of 0.06.

Karyopharm Therapeutics (NASDAQ:KPTI - Get Free Report) last announced its quarterly earnings data on Wednesday, February 19th. The company reported ($0.24) earnings per share for the quarter, beating the consensus estimate of ($0.26) by $0.02. The company had revenue of $30.54 million for the quarter, compared to analyst estimates of $30.29 million. On average, equities research analysts anticipate that Karyopharm Therapeutics Inc. will post -0.71 earnings per share for the current year.

Hedge Funds Weigh In On Karyopharm Therapeutics

Institutional investors have recently made changes to their positions in the stock. Geode Capital Management LLC raised its holdings in shares of Karyopharm Therapeutics by 3.3% in the 3rd quarter. Geode Capital Management LLC now owns 1,355,392 shares of the company's stock worth $1,125,000 after acquiring an additional 43,856 shares during the last quarter. GSA Capital Partners LLP increased its stake in Karyopharm Therapeutics by 80.6% in the 3rd quarter. GSA Capital Partners LLP now owns 1,775,700 shares of the company's stock valued at $1,474,000 after buying an additional 792,283 shares during the last quarter. FMR LLC increased its stake in Karyopharm Therapeutics by 26.1% in the 3rd quarter. FMR LLC now owns 369,723 shares of the company's stock valued at $307,000 after buying an additional 76,510 shares during the last quarter. Jane Street Group LLC increased its stake in Karyopharm Therapeutics by 265.5% in the 4th quarter. Jane Street Group LLC now owns 748,306 shares of the company's stock valued at $506,000 after buying an additional 543,556 shares during the last quarter. Finally, Focus Partners Wealth purchased a new stake in Karyopharm Therapeutics in the 4th quarter valued at about $31,000. Institutional investors and hedge funds own 66.44% of the company's stock.

About Karyopharm Therapeutics

Karyopharm Therapeutics Inc, a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States. The company discovers, develops, and commercializes novel and small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1).